Allied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale University

Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned between Allied Minds

and Bristol-Myers Squibb Company

, announced that it has entered into a worldwide licensing agreement with Yale University for a proprietary platform technology and associated lead molecules that will be further developed to treat diseases such as prostate cancer, a leading cause of cancer-related deaths among American men. Developed by Professor David A. Spiegel, Ph.D., M.D. and his team at Yale University, the proprietary synthetic molecules, known as Antibody Recruiting Molecules (ARMs), work by harnessing the power of the body's own immune system to treat cancer. The ARMs do this by recruiting antibodies already present in the bloodstream and then leading